Sellas Life Sciences Group Inc Financials

SLS

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

2/9

Sellas Life Sciences Group Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.15x

For every $1 of reported earnings, Sellas Life Sciences Group Inc generates $1.15 in operating cash flow (-$35.4M OCF vs -$30.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Sellas Life Sciences Group Inc (SLS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

-$30.9M

YoY+17.3%

Sellas Life Sciences Group Inc reported -$30.9M in net income in fiscal year 2024. This represents an increase of 17.3% from the prior year.

EPS (Diluted)

$-0.50

YoY+62.7%

Sellas Life Sciences Group Inc earned $-0.50 per diluted share (EPS) in fiscal year 2024. This represents an increase of 62.7% from the prior year.

Cash & Debt

$13.9M

YoY+448.9%

5Y CAGR+13.8%

10Y CAGR-5.2%

Sellas Life Sciences Group Inc held $13.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

74M

YoY+130.2%

5Y CAGR+70.9%

Sellas Life Sciences Group Inc had 74M shares outstanding in fiscal year 2024. This represents an increase of 130.2% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$19.1M

YoY-20.5%

5Y CAGR+21.3%

10Y CAGR-3.6%

Sellas Life Sciences Group Inc invested $19.1M in research and development in fiscal year 2024. This represents a decrease of 20.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SLS Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$0-100.0%	$1.0M-86.8%	$7.6M+300.0%	$1.9M	$0
Cost of Revenue	$0	$0-100.0%	$100K-50.0%	$200K	$0	N/A
Gross Profit	N/A	$0-100.0%	$900K-87.8%	$7.4M+289.5%	$1.9M	N/A
R&D Expenses	$19.1M-20.5%	$24.0M+18.4%	$20.3M+29.3%	$15.7M+68.9%	$9.3M+27.4%	$7.3M
SG&A Expenses	$12.4M-10.4%	$13.9M+10.2%	$12.6M+11.1%	$11.3M+17.9%	$9.6M-3.3%	$9.9M
Operating Income	-$31.5M+16.8%	-$37.9M+9.7%	-$42.0M-65.8%	-$25.3M-48.9%	-$17.0M+15.3%	-$20.0M
Interest Expense	N/A	$525K+65.6%	$317K+5183.3%	$6K-76.9%	$26K-78.0%	$118K
Income Tax	$0	$0	$0+100.0%	-$237K-1294.1%	-$17K+79.0%	-$81K
Net Income	-$30.9M+17.3%	-$37.3M+9.6%	-$41.3M-99.5%	-$20.7M-23.5%	-$16.8M+13.1%	-$19.3M
EPS (Diluted)	$-0.50+62.7%	$-1.34+37.1%	$-2.13-59.0%	$-1.34+36.5%	$-2.11	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Cost of Revenue	$0	$0	$0	$0	$0	$0	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
R&D Expenses	$4.2M+8.9%	$3.9M+20.8%	$3.2M-26.5%	$4.4M-15.9%	$5.2M+1.5%	$5.1M+0.3%	$5.1M-12.3%	$5.8M
SG&A Expenses	$2.9M-4.5%	$3.0M+5.0%	$2.9M-3.7%	$3.0M+21.8%	$2.4M-46.3%	$4.5M+47.2%	$3.1M-13.2%	$3.5M
Operating Income	-$7.1M-3.1%	-$6.9M-13.4%	-$6.1M+17.3%	-$7.3M+3.8%	-$7.6M+21.0%	-$9.6M-18.0%	-$8.2M+12.6%	-$9.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$79K+92.7%	$41K-56.4%	$94K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.8M-2.9%	-$6.6M-13.6%	-$5.8M+18.2%	-$7.1M+4.8%	-$7.5M+21.9%	-$9.6M-17.6%	-$8.1M+12.2%	-$9.3M
EPS (Diluted)	$-0.06+14.3%	$-0.070.0%	$-0.07+30.0%	$-0.10+23.1%	$-0.13+38.1%	$-0.21+8.7%	$-0.23+30.3%	$-0.33

SLS Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$19.4M+212.5%	$6.2M-70.3%	$20.9M-20.3%	$26.3M-42.9%	$46.0M+177.3%	$16.6M
Current Assets	$16.3M+414.7%	$3.2M-82.1%	$17.8M-22.9%	$23.0M-37.6%	$36.9M+348.0%	$8.2M
Cash & Equivalents	$13.9M+448.9%	$2.5M-85.2%	$17.1M-19.8%	$21.4M-39.5%	$35.3M+385.1%	$7.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0	N/A	N/A
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$10.0M-29.8%	$14.2M-11.8%	$16.1M+171.5%	$5.9M-67.2%	$18.1M+72.0%	$10.5M
Current Liabilities	$9.5M-30.8%	$13.7M-11.5%	$15.5M+211.4%	$5.0M-59.6%	$12.3M+133.2%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.5M+218.7%	-$8.0M-264.4%	$4.9M-76.2%	$20.3M-27.2%	$28.0M+358.9%	$6.1M
Retained Earnings	-$248.1M-14.2%	-$217.2M-20.8%	-$179.9M-29.8%	-$138.6M-17.6%	-$117.9M-16.6%	-$101.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$51.6M+59.6%	$32.3M-7.6%	$35.0M+79.9%	$19.4M+28.5%	$15.1M-38.1%	$24.4M+292.9%	$6.2M-23.1%	$8.1M
Current Assets	$49.1M+66.6%	$29.4M-7.9%	$32.0M+95.8%	$16.3M+32.7%	$12.3M-42.8%	$21.5M+577.8%	$3.2M-39.0%	$5.2M
Cash & Equivalents	$44.3M+75.2%	$25.3M-10.9%	$28.4M+104.5%	$13.9M+51.8%	$9.1M-50.3%	$18.4M+627.9%	$2.5M-36.3%	$4.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M
Total Liabilities	$5.9M-3.8%	$6.2M-14.5%	$7.2M-27.8%	$10.0M-18.3%	$12.2M-17.2%	$14.8M+3.9%	$14.2M+19.2%	$11.9M
Current Liabilities	$5.9M-1.2%	$6.0M-12.9%	$6.9M-27.6%	$9.5M-21.0%	$12.0M-16.6%	$14.4M+5.1%	$13.7M+17.0%	$11.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$45.6M+74.5%	$26.1M-5.8%	$27.8M+193.3%	$9.5M+224.9%	$2.9M-69.9%	$9.7M+221.4%	-$8.0M-108.4%	-$3.8M
Retained Earnings	-$267.3M-2.6%	-$260.5M-2.6%	-$253.9M-2.3%	-$248.1M-5.9%	-$234.3M-3.3%	-$226.8M-4.4%	-$217.2M-3.9%	-$209.1M

SLS Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$35.4M-12.7%	-$31.4M-31.9%	-$23.8M+8.5%	-$26.0M-149.8%	-$10.4M+41.0%	-$17.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0+100.0%	-$5.5M-22.2%	-$4.5M	$0	N/A	N/A
Financing Cash Flow	$46.8M+109.5%	$22.3M-7.3%	$24.1M+99.4%	$12.1M-68.6%	$38.4M+96.4%	$19.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	$0
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$7.1M+3.6%	-$7.3M+19.2%	-$9.1M-26.8%	-$7.2M+26.1%	-$9.7M+10.0%	-$10.8M-123.0%	-$4.8M+30.0%	-$6.9M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0	N/A	N/A	$0+100.0%	-$3.0M
Financing Cash Flow	$26.1M+516.8%	$4.2M-82.1%	$23.6M+294662.5%	$8K-98.1%	$414K-98.4%	$26.6M+686.9%	$3.4M+6170.4%	$54K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SLS Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	90.0%-7.4pp	97.4%-2.6pp	100.0%	N/A
Operating Margin	N/A	N/A	-4195.0%-3862.2pp	-332.8%+561.0pp	-893.8%	N/A
Net Margin	N/A	N/A	-4130.1%-3857.7pp	-272.4%+609.6pp	-881.9%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-158.9%+441.5pp	-600.4%-403.2pp	-197.2%-118.4pp	-78.8%-42.4pp	-36.4%+79.8pp	-116.1%
Current Ratio	1.72+1.5	0.23-0.9	1.14-3.5	4.63+1.6	2.99+1.4	1.56
Debt-to-Equity	1.05+2.8	-1.78-5.1	3.32+3.0	0.29-0.4	0.65-1.1	1.73
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-13.2%+7.3pp	-20.4%-3.8pp	-16.6%+10.2pp	-26.8%+22.6pp	-49.4%-10.3pp	-39.1%+91.7pp	-130.8%-16.2pp	-114.6%
Current Ratio	8.28+3.4	4.91+0.3	4.64+2.9	1.72+0.7	1.02-0.5	1.49+1.3	0.23-0.2	0.44
Debt-to-Equity	0.13-0.1	0.24-0.0	0.26-0.8	1.05-3.1	4.19+2.7	1.52+3.3	-1.78+1.3	-3.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Tiziana Life Sciences Ltd Com TLSA

$176.9M

Elicio Therapeutics, Inc. ELTX

$147.6M

Tenaya Therapeutics, Inc. TNYA

$142.9M

COGNITION THERAPEUTICS INC CGTX

$98.9M

Entrada Therapeutics, Inc. TRDA

$415.8M

Frequently Asked Questions

Is Sellas Life Sciences Group Inc profitable?

No, Sellas Life Sciences Group Inc (SLS) reported a net income of -$30.9M in fiscal year 2024.

What is Sellas Life Sciences Group Inc's earnings per share (EPS)?

Sellas Life Sciences Group Inc (SLS) reported diluted earnings per share of $-0.50 for fiscal year 2024. This represents a 62.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Sellas Life Sciences Group Inc's operating cash flow?

Sellas Life Sciences Group Inc (SLS) generated -$35.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Sellas Life Sciences Group Inc's total assets?

Sellas Life Sciences Group Inc (SLS) had $19.4M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Sellas Life Sciences Group Inc spend on research and development?

Sellas Life Sciences Group Inc (SLS) invested $19.1M in research and development during fiscal year 2024.

How many shares does Sellas Life Sciences Group Inc have outstanding?

Sellas Life Sciences Group Inc (SLS) had 74M shares outstanding as of fiscal year 2024.

What is Sellas Life Sciences Group Inc's current ratio?

Sellas Life Sciences Group Inc (SLS) had a current ratio of 1.72 as of fiscal year 2024, which is generally considered healthy.

What is Sellas Life Sciences Group Inc's debt-to-equity ratio?

Sellas Life Sciences Group Inc (SLS) had a debt-to-equity ratio of 1.05 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sellas Life Sciences Group Inc's return on assets (ROA)?

Sellas Life Sciences Group Inc (SLS) had a return on assets of -158.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Sellas Life Sciences Group Inc's cash runway?

Based on fiscal year 2024 data, Sellas Life Sciences Group Inc (SLS) had $13.9M in cash against an annual operating cash burn of $35.4M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sellas Life Sciences Group Inc's Piotroski F-Score?

Sellas Life Sciences Group Inc (SLS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sellas Life Sciences Group Inc's earnings high quality?

Sellas Life Sciences Group Inc (SLS) has an earnings quality ratio of 1.15x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.